

Curriculum Vitae

Contact information

Name: Catia MARZOLINI KRAUSER
Professional address: Division of Infectious Diseases & Hospital Epidemiology
Departments of Medicine and Clinical research
University Hospital of Basel and University of Basel
E-mail: catia.marzolini@usb.ch

Education/Academic recognition

2018 "Titular Professur" (Associate Professor)
University of Basel, Switzerland
2013 "Venia docendi", PD
University of Basel, Switzerland
2006 Fellowship in Clinical Pharmacology
Vanderbilt University, Nashville, USA
2002 Ph.D. in Pharmaceutical Sciences
University of Lausanne, Switzerland
1996 Diploma of Hospital Pharmacy
University hospital, Lausanne, Switzerland
1994 Swiss federal diploma of Pharmacy
University of Lausanne, Switzerland

Professional experience

2011 to present Research associate
School of Molecular and Clinical Pharmacology
University of Liverpool, UK
2017 to present Research group leader
Departement Klinische Forschung (DKF)
Division of Infectious Diseases
University hospital of Basel, Switzerland
2012-2016 Senior research scientist
Division of Infectious Diseases
University hospital of Basel, Switzerland
2007-2012 Research scientist
Division of Infectious Diseases
University hospital of Basel, Switzerland
2005-2006 Chief research fellow
Division of Clinical Pharmacology
Vanderbilt University School of Medicine, Nashville, USA
2002-2005 Research fellow
Division of Clinical Pharmacology
Vanderbilt University School of Medicine, Nashville, USA
1998-2002 PhD student

	Division of Clinical Pharmacology University hospital of Lausanne, Switzerland
1996-1998	Clinical pharmacist SOS Pharmaciens (home care), Geneva, Switzerland
1995-1996	Master student Hospital pharmacy University hospital, Lausanne, Switzerland
1993-1995	Substitute pharmacist in retail pharmacies

Professional activity and public service

A) Panel memberships

2015 to present	Swiss HIV Cohort Study (SHCS) scientific board
2013 to present	European AIDS Clinical Society (EACS) guidelines

B) Organization memberships

2019 to present	Editorial Board of Clinical Cases DDIs website
2018 to present	Editorial Board of the journal: <i>HIV Medicine</i> .
2012 to present	Editorial Board of the journal: <i>Antiviral Therapy</i> .
2009 to present	Editorial Board, University of Liverpool HIV Drug Interactions database: www.HIV-druginteractions.org (a website highly used for the care of HIV patients worldwide). <u>C. Marzolini leads the content development of the HIV drug interactions website</u>).
2020	Scientific Program committee for the 15 th International Congress on drug therapy in HIV infection, (October 25-28, 2020).
2019	Local co-chair for the 21 st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV (November 5-6, 2019).
2019	Scientific Program committee for the 17 th European AIDS Conference (November 6-9, 2019).
2018	Scientific Program committee for the 14 th International Congress on drug therapy in HIV infection, (October 28-31, 2018).
2015	Scientific Program committee for the 15 th European AIDS Conference (October 21-24, 2015).
2013	Scientific Program committee for the 14 th European AIDS Conference (October 16-19, 2013).

Honors

2019	“Award for the best HIV/AIDS App in 2019” by healthline (medical information and trusted health advice, www.healthline.com).
------	---

2017-2018	2017 SHCS AbbVie Prize for the research project on model-based simulation and clinical validation of drug-drug interactions in the SHCS.
2016	“Award for the best HIV/AIDS App in 2016” by healthline (medical information and trusted health advice, www.healthline.com).
2014	“Excelling at Innovation Award” from the University of Liverpool, UK.
2005	Clinical Pharmacology Fellow - Teaching Award, Div. of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, USA.
2003	Claude V. Perrier Foundation Prize for the research in pharmacotherapy, Geneva, Switzerland, for the work performed in the field of the pharmacogenetics of antiretroviral agents.

Funding (individual- and project- related)

2020	2020 Project related funding from the Swiss National Science Foundation, Bern, Switzerland for the project: Use of physiologically based pharmacokinetic modelling to simulate dosing requirements of long-acting intramuscular antiretroviral drugs in special populations and to manage drug-drug interactions (491'138 CHF).
2017	Project funding from the Swiss Tropical and Public Health Institute for the study: prevalence of actual clinically relevant drug-drug interactions in the KIULARCO Cohort (50'000 CHF) (C. Marzolini is co-applicant).
2016	Project funding from the Swiss HIV Cohort Study for the study: Prevalence of potentially inappropriate medication use in elderly patients of the SHCS (23'378 CHF).
2016	Project funding from the OPO Stiftung, Zürich, for the project: Development of permeability rate limited physiologically based pharmacokinetic models to simulate drug-drug interactions at the hepatic level (100'000 CHF).
2016	Project related funding from the Swiss National Science Foundation, Bern, Switzerland for the project: Use of physiologically based pharmacokinetic modelling to simulate drug-drug interactions between antiretroviral drugs and commonly prescribed co-medications in the aging HIV population (359'718 CHF).
2014	Project funding from Janssen for the study: Effect of cobicistat versus ritonavir boosting on the brain permeation of darunavir (101'780 CHF).
2013	Individual funding (Förderung exzellenter junger Forscher) for 12 months from the University of Basel (80'000 CHF).

2011	Project funding from Janssen for the study: Permeation of antiretroviral agents across the blood-brain barrier (74'700 CHF).
2010	Project funding from the Swiss HIV Cohort Study and from the "Stiftung Forschung Infektionskrankheiten", University Hospital Basel" for the study: Effect of SLCO1B1 521T>C polymorphism on the lipid-lowering response to statins and on the potential risk of muscle toxicity in HIV infected patients treated with lopinavir/r containing regimens (44'332 CHF).
2009	Project funding from the Swiss HIV Cohort Study and from the "Stiftung Forschung Infektionskrankheiten", University Hospital Basel for the study: Determinants of virological suppression in antiretroviral treated patients with self-reported poor adherence (45'772 CHF).
2008	Project funding from the Swiss HIV Cohort Study for the study: Drug-drug interactions in a large HIV cohort study (60'397 CHF).
2008	Individual funding (Marie Heim-Vögtlin) for 18 months from the Swiss National Science Foundation, Bern, Switzerland (110'872 CHF).
2005	Research fellowship funding for 12 months from the Swiss National Science Foundation, Bern, Switzerland (39'900 CHF).
2003	Research fellowship funding for 12 months from the Swiss National Science Foundation, Bern, Switzerland (39'900 CHF).

Publications

H-index = 27 (27 items that have 27 citations or more)

Sum of times cited citations: 4092

A) Peer-reviewed journals

- 1) Back D, **Marzolini C**, Hodge C, Marra F, Boyle A, Gibbons S, Burger D, Khoo S. COVID-19 treatment in patients with comorbidities: Awareness of drug-drug interactions. *Br J Clin Pharmacol* [epub ahead of print].
- 2) Stader F, Khoo S, Stoeckle M, Back DJ, Hirsch HH, Battegay M, **Marzolini C**. Stopping lopinavir/ritonavir in COVID-19 patients: Duration of the drug interacting effect. *J Antimicrob Chemother* [in press].
- 3) Deutschmann E, Bucher HC, Jaeckel S, Gibbons S, McAllister K, Scherrer A, Braun D, Cavassini M, Hachfeld H, Calmy A, Battegay M, Cipriani M, Elzi L, Young J, Lopez-Centeno B, Berenguer J, Khoo S, Moffa G, **Marzolini C**. Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors. *Clin Infect Dis* [in press].
- 4) Lopez-Centeno B, Badenes C, Mataix A, Bellon JM, Perez-Latorre L, Lopez JC, Benedi J, Khoo S, **Marzolini C**, Calvo MJ, Berenguer J. Potentially inappropriate medications in older adults living with HIV. *HIV Medicine* [in press].

- 5) Courlet P, Alves Saldanha S, Cavassini M, **Marzolini C**, Andre P, Buclin T, Desfontaine V, Decosterd LA. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine and rilpivirine in plasma of people living with HIV. *Mass Spectrometry* [epub ahead of print].
- 6) Bukkems VE, Colbers A, **Marzolini C**, Molto J, Burger DM. Drug-drug interactions with antiretroviral drugs in pregnant women living with HIV: are they different from non-pregnant subjects? *Clin Pharmacokinet* [in press].
- 7) Courlet P, Livio F, Alves Saldanha S, Scherrer A, Battegay M, Cavassini M, Stoeckle M, Decosterd LA, **Marzolini C*** and the Swiss HIV Cohort Study. Real-life management of drug-drug interactions between antiretrovirals and statins. *J Antimicrob Chemother* 2020. * corresponding author [epub ahead of print].
- 8) Burger DM, Calmy A, **Marzolini C**. Cobicistat: a case of mislabeled drug-drug interaction risk? *B J Clin Pharmacol* 2020;86:834-836.
- 9) Ryom L, Cotter A, Buckley RDM, Béguelin C, Podlekareva D, Arribas J, **Marzolini C**, Mallon PGM, Rauch A, Kirk O, Molina JM, Guaraldi G, Winston A, Bhagani S, Cinque P, Kowalska J, Collins S, Battegay M on behalf of the EACS Governing Board. 2019 update of the European AIDS Clinical Society (EACS) Guidelines for treatment of people living with HIV (PLWHV) version 10.0. *HIV Medicine* [in press].
- 10) Roth JA, Radevski G, **Marzolini C**, Rauch A, Günthard HF, Kouyos RD, Fux CA, Scherrer AU, Calmy A, Cavassini M, Kahlert CR, Bernasconi E, Bogojeska J, Battegay M and the Swiss HIV Cohort Study. Cohort-derived machine learning models for individual prediction of chronic kidney disease in people living with HIV: a prospective multicenter cohort study. *J Infect Dis* 2020 [epub ahead of print].
- 11) Guaraldi G, Maurice J, **Marzolini C**, Milic J, Tsochatzis E, Sebastiani G on behalf of SHIVER Network. New drugs for non-alcoholic steatohepatitis and HIV infection: Great expectations with a great absent? *Hepatology*. 2020;71:1831-44.
- 12) Courlet P, Decosterd LA, Alves Saldanha S, Cavassini M, Stader S, Stoeckle M, Buclin T, **Marzolini C**, Guidi M, Csajka C and the Swiss HIV Cohort Study. Influence of drug-drug interactions on the pharmacokinetics of atorvastatin and its major active metabolite ortho-OH-atorvastatin in aging people living with HIV. *Clin Pharmacokinet* 2020 [epub ahead of print].
- 13) Courlet P, Livio F, Guidi M, Cavassini M, Battegay M, Stoeckle M, Buclin T, Alves Saldanha S, Csajka C, **Marzolini C****, Decosterd L and the Swiss HIV Cohort Study. Polypharmacy, inappropriate drugs and drug-drug interactions in people living with HIV. *Open Forum Infect Dis*. 2019;6(12):ofz531. **equal last author contribution.
- 14) Stader F, Decosterd L, Stoeckle M, Cavassini M, Battegay M, Alves Saldanha S, **Marzolini C**, Courlet P and the Swiss HIV Cohort Study. Aging does not impact drug-drug interaction magnitudes with antiretrovirals: a Swiss HIV Cohort Study. *AIDS* 2020;34(6):949-952.
- 15) Stader F, Courlet P, Kinvig H, Battegay M, Decosterd LA, Penny MA, Siccardi M, **Marzolini C**. Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. *Br J Clin Pharmacol* [epub ahead of print].
- 16) Back DJ, **Marzolini C**. The challenge of HIV treatment in an era of polypharmacy. *J Int AIDS Soc*, 2020;23:e25449.
- 17) Courlet P, Stader F, Guidi M, Alves Saldanha SA, Stoeckle M, Cavassini M, Battegay M, Buclin T, Decosterd LA, **Marzolini C**. Pharmacokinetic profiles of boosted darunavir, dolutegravir and

lamivudine in aging patients enrolled in the Swiss HIV Cohort Study. *AIDS*. 2020;34:103-108. * corresponding author

- 18) Schlaeppi C, Vanobberghen F, Sikalengo G, Glass TR, Ndege RC, Foe G, Kuemmerle A, Paris D, Battegay, **Marzolini C**, Weisser M on behalf of the KIULARCO study group. Prevalence and management of drug-drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania. A prospective cohort study. *HIV Medicine*. 2020;21(1):53-63.
- 19) Courlet P, Spaggiari D, Desfontaine V, Cavassini M, Alves Saldanha S, Buclin T, **Marzolini C**, Csajka C, Decosterd L. UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. *J Chromatogr B*. 2019;1125:121733.
- 20) Lopez-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan A, McAllister K, Bellon JM, Gibbons S, Balsalobre P, Perez-Latorre L, Benedi J, **Marzolini C**, Aranguren-Oyarzabal A, Khoo S, Calvo-Alcantara MF, Berenguer J. Polypharmacy and drug-drug interactions in HIV infected subjects in the region of Madrid, Spain: a population-based study. *Clin Infect Dis*. 2019 [epub ahead of print].
- 21) Stader F, Kinvig H, Penny MA, Battegay M, Siccardi M, **Marzolini C**. Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving drug exposure changes in the elderly. *Clin Pharmacokinet*. 2020;59(3):383-401.
- 22) Boyle A, Moss CE, **Marzolini C**, Khoo S. Clinical pharmacodynamics, pharmacokinetics and drug interaction profile of doravirine. *Clin Pharmacokinet*. 2019;58(12):1553-1565.
- 23) Livio F, **Marzolini C***. Prescribing issues in elderly individuals living with HIV: thinking beyond drug-drug interactions with antiretroviral drugs. *Ther Adv Drug Saf*. 2019;10:1-7. * corresponding author
- 24) Sundermann EE, Erlandson KM, Pope C, Rubtsova A, Montoya J, Moore A, **Marzolini C**, O'Brien K, Pahwa S, Payne B, Rubin LH, Walmsley S, Haughey NJ, Montano M, Margolick J, Moore DJ. Current challenges and solutions in research and clinical care of the older persons living with HIV: findings presented at the 9th International Workshop of HIV and Aging. *AIDS Res Hum Retroviruses*. 2019;35(11/12):985-998.
- 25) **Marzolini C***, Livio F. Prescribing issues in elderly individuals living with HIV. *Expert Rev Clin Pharmacol*. 2019;12:643-659. * corresponding author
- 26) Courlet P, Guidi M, Glatard A, Alves Saldanha S, Cavassini M, Buclin T, **Marzolini C**, Eap CB, Decosterd L, Csajka C and the Swiss HIV Cohort Study. Escitalopram population pharmacokinetics in people living with HIV and psychiatric population: drug-drug interactions and probability of target attainment. *Br J Clin Pharmacol*. 2019;85(9):2022-2032.
- 27) Courlet P, Decosterd LA, Brown JA, Alves Saldanha S, **Marzolini C**, Cavassini M, Stoeckle M, Csajka C, Labhardt N, Calmy A and the Swiss HIV Cohort Study. Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. *J Antimicrob Chemother*. 2019;74:2468-2470.
- 28) Brockhaus L, Goldblum D, Eggenschwiler L, Zimmerli S, **Marzolini C**. Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. *Clin Microbiol Infect*. 2019;25(11):1364-1369.
- 29) Ruffieux Y, Lemsalu L, Aebi-Popp K, Calmy A, Cavassini M, Fux C, Günthard H, **Marzolini C**, Scherrer A, Vernazza P, Keiser O, Egger M for the Swiss HIV Cohort Study. Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017. *J Int AIDS Soc*. 2019; 22(8):e25339.

- 30) Stader F, Penny M, Siccardi M, **Marzolini C**. A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab. *CPT Pharmacometrics Syst Pharmacol*. 2019;8:444-459.
- 31) Hodel EM, **Marzolini C**, Waitt C, Rakhmanina N. Pharmacokinetics, placental and breastmilk transfer of antiretroviral drugs in pregnant and lactating women living with HIV. *Curr Pharm Des*. 2019;25:556-576.
- 32) Stader F, Siccardi M, Battegay M, Kinvig H, Penny MA, **Marzolini C**. Repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological and biological age-dependent changes. *Clin Pharmacokinet*. 2019;58:483-501.
- 33) Baettig V, Courlet P, Delko T, Battegay M, **Marzolini C***. Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in the early and late post-gastric bypass surgery periods. *AIDS*. 2018;32:1903-1905. *corresponding author
- 34) Stader F, Kinvig H, Battegay M, Khoo S, Owen A, Siccardi M, **Marzolini C***. Analysis of clinical drug-drug interaction data to predict uncharacterized interaction magnitudes between antiretroviral drugs and co-medications. *Antimicrob Agents Chemother*. 2018;62:e00717-18. *corresponding author
- 35) Ryom L, Boesecke C, Bracchi M, Ambrosioni J, Pozniak A, Arribas J, Behrens G, Mallon PGM, Puoti M, Rauch A, Miro JM, Kirik O, **Marzolini C**, Lundgren JD, Battegay M. Highlights of the 2017 European AIDS Clinical Society Guidelines for the treatment of adult HIV positive persons Version 9.0. *HIV Med*. 2018;19:309-315.
- 36) Engel T, Raffenberg M, **Marzolini C**, Cavassini M, Kovari H, Hasse B, Tarr PE. HIV and Aging – perhaps not quite as bad as we feared?. *Gerontology*. 2018;15:1-11
- 37) Courlet P, Spaggiari D, Cavassini M, Du Pasquier R, Alves Saldanha S, Buclin T, **Marzolini C**, Csajka C, Decosterd L. Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. *Clinical Mass Spectrometry*. 2018;8:8-20.
- 38) Bartels H, Decosterd L, Battegay M, **Marzolini C***. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. *J Antimicrob Chemother*. 2017; 72:2574-2577. *corresponding author
- 39) **Marzolini C***, Decosterd L, Winterfeld U, Tissot F, Francini K, Buclin T, Livio F. Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum. *Br J Clin Pharmacol*. 2017; 83:2835-2838. * corresponding author
- 40) Piso R, Battegay M, **Marzolini C**. Dolutegravir plasma levels after gastric bypass surgery. *AIDS*. 2017; 31:1052-1054.
- 41) Seden K, Gibbons S, **Marzolini C**, Schapiro JM, Burger DM, Back DJ, Khoo S. Development of an Evidence Evaluation and Synthesis System for Drug-Drug Interactions, and its Application to a Systematic Review of HIV and Malaria Co-infection. *PLoS One*. 2017; 12:e0173509.
- 42) Erb S, Letang E, Glass TR, Natamatungiro A, Mnzava D, Mapesi E, Haschke M, Duthalder U, Berger B, Muri L, Bader J, **Marzolini C**, Elzi L, Klimkait T, Langewitz W, Battegay M for the Kiularco Study Group. Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems. *HIV Medicine*. 2017; 18:623-634.
- 43) **Marzolini C***, Rajoli RK, Battegay M, Elzi L, Back D, Siccardi M. Physiologically based pharmacokinetic modeling to predict drug-drug interactions with efavirenz involving

simultaneous inducing and inhibitory effects on cytochromes. Clin Pharmacokinet. 2017; 56:409-420. * corresponding author

- 44) **Marzolini C***, Gibbons S, Khoo S, Back D. Cobicistat versus ritonavir boosting and differences in the drug-drug interactions profile with co-medications. J Antimicrob Chemother. 2016; 71:1755-8. * corresponding author
- 45) McLaren PJ, Raisaro JL, Aouri M, Rotger M, Ayday E, Bartha I, Delgado MB, Vallet Y, Gunthard H, Cavassini M, Furrer H, Lecompte T, **Marzolini C**, Schmid P, Di Benedetto C, Decosterd LA, Fellay J, Hubaux JP, Telenti A and the Swiss HIV Cohort Study. Privacy preserving pharmacogenetic testing in the clinic – a real-life implementation in HIV treatment. Genetics in Medicine. 2016; 18:814-22.
- 46) Moss DM, **Marzolini C**, Rajoli RKR, Siccardi M. Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. Expert Opin Drug Metab Toxicol. 2015; 11:1203-17.
- 47) **Marzolini C***, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca J, Fehr J, Bonora S, Mocroft A, Obel N, Dauchy FA, Zangerle R, Gogos C, Gianotti N, Ammassari A, Torti C, Ghosn J, Chêne G, Grarup J, Battegay M for the Efavirenz and Obesity Project Team on behalf of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment naive adults. AIDS. 2015; 29: 193-200. * corresponding author
- 48) Hasse B, Iff M, Ledergerber B, Calmy A, Schmid P, Hauser C, Cavassini M, Bernasconi E, **Marzolini C**, Tarr P. Obesity trends and body mass index changes after starting antiretroviral treatment: the Swiss HIV Cohort Study. Open Forum Infect Dis 2014; 1 (2).
- 49) Kurz M, Stoeckle M, Krasniqi F, Battegay M, **Marzolini C***. Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma. Int J STD AIDS. 2015; 26:212-214. * corresponding author
- 50) Lakatos B, Stoeckle M, Elzi L, Battegay M, **Marzolini C***. Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. Swiss Med Wkly. 2014; 144:w13906. * corresponding author
- 51) **Marzolini C***, Mueller R, Li-Blatter X, Battegay M, Seelig A. The brain entry of HIV-1 protease inhibitors is facilitated when used in combination. Mol Pharm. 2013; 10:2340-2349. * corresponding author
- 52) Siccardi M, **Marzolini C**, Seden K, Almond L, Kirov A, Khoo S, Owen A, Back D. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Clin Pharmacokinet. 2013; 52:583-92.
- 53) Lubomirov R, Arab-Alameddine M, Rotger M, Fayet-Mello A, Martinez R, di Iulio J, Cavassini M, Gunthard H, Furrer H, **Marzolini C**, Bernasconi E, Calmy A, Buclin T, Decosterd L, Csajka C, Telenti A and the Swiss HIV Cohort Study. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenet Genomics. 2013; 23:9-18.
- 54) **Marzolini C***, Gray G. Maternal antiretroviral prophylaxis and breastfeeding. Antivir Ther. 2012; 17:1503-1506. * corresponding author
- 55) de Roche, Siccardi M, Stoeckle M, Livio F, Back D, Battegay M, **Marzolini C***. Efavirenz in an obese HIV-infected patient – case report and *in vitro in vivo* extrapolation model indicate risk of underdosing. Antivir Ther. 2012; 17:1381-1384. * corresponding author

- 56) Siccardi M, Almond L, Schipani A, Csajka C, **Marzolini C**, Wyen C, Brockmeyer NH, Boffito M, Owen A, Back D. Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. *Clin Pharm Ther.* 2012; 92:494-502.
- 57) Glass TR, Rotger M, Telenti A, Decosterd L, Bucher H, Rickenback M, Günthard H, Vernazza P, Hirschel B, Bernasconi E, Furrer H, Battegay M, **Marzolini C*** and the Swiss HIV Cohort Study. Determinants of virological suppression in HIV positive patients on antiretroviral therapy with self-reported poor adherence. *PLoS One.* 2012; 7:e29186. * corresponding author
- 58) Mossdorf E, **Marzolini C**, Fasel D, Mello Fayet A, Blum C, Donath M, Battegay M. Drug-drug interactions with HIV treatments. *Praxis (Bern 1994).* 2011; 100:1193-6.
- 59) **Marzolini C***, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, Elzi L and the Swiss HIV Cohort Study. Aging with HIV: medication use and risk for potential drug-drug interactions. *J Antimicrob Chemother.* 2011; 66:2107-2111. * corresponding author
- 60) **Marzolini C***, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave JP, Cavassini M, Bernasconi E, Calmy A, Vernazza P, Khoo S, Ledergerber B, Back DJ, Battegay M and the Swiss HIV Cohort Study. Prevalence of co-medications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. *AntivirTher.* 2010; 15:413-423. * corresponding author
- 61) Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, **Marzolini C**, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd L, Csajka C, Telenti A. and the Swiss HIV Cohort Study. ADME pharmacogenetics – investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. *Pharmacogenetics and Genomics.* 2010; 20:217-30.
- 62) Elzi L, **Marzolini C**, Furrer H, Ledergerber B, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Weber R, Battegay M. Treatment modification in HIV-infected individuals starting combination antiretroviral therapy between 2005-2008: rates, time point and regimen specific aspects. *Arch Intern Med.* 2010; 170:57-65.
- 63) Mertz D, Battegay M, **Marzolini C**, Mayr M. Drug-drug interaction in a kidney transplant recipient with HIV salvage therapy and tacrolimus. *Am J Kidney Dis.* 2009; 54:e1-4.
- 64) Krishnamurthy P, Schwab M, Takenaka K, Nachagari D, Morgan J, Leslie M, Du W, Boyd K, Cheok M, Nakauchi H, **Marzolini C**, Kim RB, Poonkuzhali B, Schuetz E, Evans W, Relling M, Schuetz JD: Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. *Cancer Res.* 2008; 68:4983-9.
- 65) **Marzolini C**, Tirona R, Gervasini G, Poonkuzhali B, Assem M, Lee W, Leake B, Schuetz J, Schuetz E, Kim RB: A common polymorphism in the bile acid receptor FXR is associated with decreased hepatic target gene expression. *Mol Endocrinol.* 2007; 21:1769-1780.
- 66) Ribaldo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, Gulick RM, Clifford DB, **Marzolini C**, Fletcher CV, Tashima KT, Kuritzkes DR, Acosta EP. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an adult AIDS clinical trials group study. *Clin Infect Dis.* 2006; 42: 401-407.
- 67) Colombo S, Beguin A, **Marzolini C**, Telenti A, Biollaz J, Decosterd L. Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction. *J Chromatograph B.* 2006; 832: 138-143.
- 68) **Marzolini C**, Kim RB. Placental transfer of antiretroviral drugs. *Clin Pharm Ther.* 2005; 78: 118-122.

- 69) Fellay J, **Marzolini C**, Decosterd L, Powell Golay K, Baumann P, Buclin T, Telenti A, Eap CB. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. *Eur J Clin Pharmacol*. 2005; 60:865-873.
- 70) Haas DW, Ribaud HJ, Kim RB, Tierney C, Wilkinson GR, Clifford DB, Gulick RM, Hulgand T, **Marzolini C**, Acosta EP. Pharmacogenetics of efavirenz and central nervous system side effects: an adult AIDS clinical trial group study. *AIDS*. 2004; 18:2391-2400.
- 71) Colombo S, Guignard N, **Marzolini C**, Telenti A, Biollaz J, Decosterd LA. Determination of the new HIV-protease inhibitor atazanavir by HPLC after solid-phase extraction. *J Chromatograph B*. 2004; 810:25-34.
- 72) Csajka C, **Marzolini C**, Fattinger K, Decosterd LA, Telenti A, Biollaz J, Buclin T. Population pharmacokinetics and effects of indinavir in patients with human immunodeficiency virus infection. *Antimicrob Agent Chemother*. 2004; 48: 3226-3232.
- 73) **Marzolini C**, Tirona R, Kim RB. Pharmacogenomics of organic anion transporting polypeptide (OATP) and organic anion transporter (OAT) families. *Pharmacogenomics*. 2004; 5: 273-282.
- 74) Bleiber G, May M, Suarez C, Martinez R, **Marzolini C**, Egger M, Telenti A and the Swiss HIV Cohort Study: MDR1 genetic polymorphism does not modify cell permissiveness to HIV-1 or disease progression before treatment. *J Infect Dis*. 2004; 189: 583-586.
- 75) **Marzolini C**, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. *Clin Pharm Ther*. 2004; 75: 13-33.
- 76) Csajka C, **Marzolini C**, Fattinger K, Decosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. *Clin Pharm Ther*. 2003; 73: 20-30.
- 77) Doser N, Kübli S, Telenti A, **Marzolini C**, Chave JP, Feihl F, Buclin T, Pannatier A, Darioli R, Nicod P, Waeber B, Mooser V. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. *AIDS*. 2002; 16: 1982-1983.
- 78) **Marzolini C**, Béguin A, Telenti A, Schreyer A, Buclin T, Biollaz J, Decosterd LA. Determination of lopinavir and nevirapine by HPLC after solid-phase extraction: application for the assessment of their transplacental passage at delivery. *J Chromatograph B*. 2002; 774: 127-140.
- 79) **Marzolini C**, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, Buclin T and the MoCHiV. Transplacental passage of protease inhibitors at delivery. *AIDS*. 2002; 16: 889-893.
- 80) Fellay J, **Marzolini C**, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel A, Vernazza P, Eap CB, Telenti A, for the Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. *Lancet*. 2002; 359: 30-36.
- 81) **Marzolini C**, Chave JP, Telenti A, Brenas-Chinchon L, Biollaz J. Impaired absorption of rifabutin by concomitant administration of didanosine. *AIDS*. 2001; 15: 2203-2204.
- 82) **Marzolini C**, Buclin T, Decosterd LA, Biollaz J, Telenti A. Nelfinavir plasma levels under TID and BID regimens: high inter- and low intra-patient variability. *Ther Drug Monit*. 2001; 23: 394-398.
- 83) **Marzolini C**, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. *AIDS* 2001; 15: p71-75 + response to a letter *AIDS*. 2001; 15: 1193-1194.
- 84) **Marzolini C**, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB. Efavirenz decreases methadone blood concentrations. *AIDS*. 2000; 14: 1291-1292.

- 85) **Marzolini C**, Telenti A, Buclin T, Biollaz J, Decosterd LA. Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high performance liquid chromatography after solid-phase extraction. *J Chromatograph B*. 2000; 740: 43-58.
- 86) Gander M, Leyvraz S, Decosterd L, Bonfanti M, **Marzolini C**, Shen F, Liénard D, Perey L, Colella G, Biollaz J, Lejeune F, Yarosh D, Belanich M and D'Incalci M. Sequential administration of temozolomide and fotemustine: Depletion of O⁶-alkylguanine-DNA transferase in blood lymphocytes and in tumours. *Annals of Oncology*. 1999; 10: 831-838.
- 87) **Marzolini C**, Decosterd LA, Shen F, Gander M, Leyvraz S, Bauer J, Buclin T, Biollaz J and Lejeune F. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous and hepatic intra-arterial administration. *Cancer Chemother Pharmacol*. 1998; 42: 433-440.

B) Book chapters

- 1) **Marzolini C***: Les interactions médicamenteuses. In *VIH, Hépatites virales et Santé sexuelle*. 2020
- 2) Moss D, Siccardi M, **Marzolini C***: Mechanisms of drug interactions II: transport proteins. In *Drug interactions in Infectious Diseases*. Edited by Pai M, Kiser J, Gubbins P, Rodvold K. Humana Press. 2018 * corresponding author.
- 3) **Marzolini C***, Battegay M, Back DJ: Mechanisms of drug interactions II: transport proteins. In *Drug interactions in Infectious Diseases*. Edited by Piscitelli S, Rodvold KA, Pai MP. Humana Press. 2011: 43-72. * corresponding author
- 4) **Marzolini C**, Kim RB, Telenti A. Pharmacogenetics of antiretroviral agents. In *HIV Therapy*. Edited by Dolin R, Masur H, Saag MS. Churchill Livingstone. 2008: 513-538.
- 5) **Marzolini C**, Tirona R, Kim RB. Pharmacogenetics of drug transporters. In *Pharmacogenomics*. Edited by Kalow W, Meyer UA and Tyndale RF. Taylor & Francis. 2005: 109-156.

Presentations

- 1) Kinvig H, Stader F, Bunglawala F, Rajoli R, Cottura N, Howarth A, Owen A, **Marzolini C**, Siccardi M. High dose rifampicin for the treatment of leprosy in HIV patients taking dolutegravir. 27th Conference on Retroviruses and Opportunistic Infections, Boston, 8-11 March 2020 (poster).
- 2) Jakeman B, Scherrer A, Darling KEA, Nadin I, Hasse B, Hauser C, Tarr P, Calmy A, Kunze U, Stoeckle M, Schmid P, Battegay M, Du Pasquier R, Cavassini M, **Marzolini C** and the NAMACO study group a Swiss HIV Cohort Study. Effect of non-HIV drugs on neurocognitive domains in a well-treated HIV population. 27th Conference on Retroviruses and Opportunistic Infections, Boston, 8-11 March 2020 (poster).
- 3) Jakeman B, Scherrer A, Günthard H, Battegay M, Hachfeld A, Calmy A, Schmid P, Bernasconi E, Cavassini M, **Marzolini C** and the Swiss HIV Cohort Study. Anticholinergic drug use in ≥ 65 year old patients of the Swiss HIV Cohort Study. 27th Conference on Retroviruses and Opportunistic Infections, Boston, 8-11 March 2020 (poster).
- 4) Courlet P, Livio F, Saldanha SA, Scherrer AU, Battegay M, Cavassini M, Stoeckle M, Decosterd LA, **Marzolini C** and the Swiss HIV Cohort Study. Real-life management of drug-drug interactions between antiretrovirals and statins. 27th Conference on Retroviruses and Opportunistic Infections, Boston, 8-11 March 2020 (poster).
- 5) Stader F, Courlet P, Kinvig H, Battegay M, Decosterd L, Penny MA, Siccardi M, **Marzolini C**. Aging does not impact drug-drug interaction magnitudes involving antiretroviral drugs. 27th Conference on Retroviruses and Opportunistic Infections, Boston, 8-11 March 2020 (poster).

- 6) Deutschmann E, Bucher HC, Jaeckel S, Gibbons S, McAllister K, Braun D, Cavassini M, Hachfeld H, Calmy A, Battegay M, Cipriani M, Elzi L, Young J, Lopez-Centeno B, Berenguer J, Khoo S, Moffa G, **Marzolini C**. Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors.
17th European AIDS Conference (EACS), Basel, 6-9 November 2019 (**oral presentation**).
- 7) Gibbons S, **Marzolini C**, Moss K, McAllister K, Chiong J, Back D, Khoo S. Drug interactions profiles for first-line antiretroviral therapy and selected fixed dose combinations antiretroviral combinations over 20 years of the Liverpool drug interaction website.
17th European AIDS Conference (EACS), Basel, 6-9 November 2019 (**best poster oral presentation**). **Prize for the best poster**.
- 8) Lopez-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan A, Bellon-Cano JM, Balsalobre P, Perez-Latorre L, Benedi J, Khoo S, **Marzolini C**, Calvo-Alcantara MJ, Berenguer J. Potentially inappropriate medications in older adults with HIV in the region of Madrid (Spain).
17th European AIDS Conference (EACS), Basel, 6-9 November 2019 (poster).
- 9) Mugglin C, Calmy A, Günthard H, Tarr P, Atkinson A, Scherrer A, Cavassini M, **Marzolini C**, Schmid P, Bernasconi E, Braun B, Wandeler G, Rauch A, and the Swiss HIV Cohort Study. Changes in weight after switching to dolutegravir containing antiretroviral therapy in the Swiss HIV Cohort Study (SHCS).
17th European AIDS Conference (EACS), Basel, 6-9 November 2019 (**oral presentation**).
- 10) Stader F, Kinvig H, Penny MA, Battegay M, Siccardi M, **Marzolini C**. Adult age does not impact the magnitude of drug-drug interactions – a pilot study using physiologically-based pharmacokinetic modelling.
10th American Conference on Pharmacometrics, Orlando, 20-23 October 2019 (poster).
- 11) Cabanilla MG, **Marzolini C**, Conklin JE, Zarick C, Brumbach BH, Mercier RC, Jakeman B. Risk of polypharmacy and inappropriate prescribing in persons living with HIV ≥ 65 years of age.
10th IAS Conference of HIV Science, Mexico City, 21-24 July 2019 (poster).
- 12) Stader F, Kinvig H, Penny MA, Battegay M, Siccardi M, **Marzolini C**. Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving age-related changes in drug exposure in the elderly.
28th meeting on Population Approach Group Europe (PAGE), Stockholm, 11-14 June 2019 (poster).
- 13) Courlet P, Guidi M, Cavassini M, Buclin T, **Marzolini C**, Decosterd L, Csajka C. Influence of drug-drug interactions on population pharmacokinetics of atorvastatin and its active metabolite ortho-OH-atorvastatin in people living with HIV.
28th meeting on Population Approach Group Europe (PAGE), Stockholm, 11-14 June 2019 (poster).
- 14) Gibbons S, **Marzolini C**, Moss C, McAllister K, Chiong J, Back D, Khoo S. Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website.
20th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Noordwijk, 14-16 Mai 2019 (**oral presentation**).
- 15) Stader F, Kinvig H, Penny MA, Battegay M, Siccardi M, **Marzolini C**. Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV.
20th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Noordwijk, 14-16 Mai 2019 (**short oral presentation**). **Prize for the best short oral presentation**.

- 16) Stader F, Siccardi M, Kinvig H, Battegay M, Penny M, **Marzolini C**. Drug-drug interaction magnitudes in young vs elderly: example of rivaroxaban-darunavir/r.
26th Conference on Retroviruses and Opportunistic Infections, Seattle, 4-7 March 2019 (poster).
- 17) Kinvig H, Stader F, Roberts O, Owen A, **Marzolini C**, Siccardi M. The role of OATP1B1 in grazoprevir drug-drug interactions and the elderly.
26th Conference on Retroviruses and Opportunistic Infections, Seattle, 4-7 March 2019 (poster).
- 18) Courlet P, **Marzolini C**, Cavassini M, Battegay M, Alves Saldanha S, Alves D, Waelti Da Costa V, Csajka C, Decosterd L. Polypharmacy, inappropriate drugs, and drug-drug interactions in HIV-infected elderly.
26th Conference on Retroviruses and Opportunistic Infections, Seattle, 4-7 March 2019 (poster).
- 19) Livio F, Rustemi F, Moffa G, Elzi L, Stader F, Braun D, Calmy A, Hachfeld A, Cavassini M, Tarr P, Wissel K, Battegay M, **Marzolini C**. Polypharmacy, drug-drug interactions and potentially inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study.
Clinical Research Day at the University Hospital Basel, Basel, 24 January 2019 (**oral presentation**).
- 20) Livio F, Rustemi F, Moffa G, Elzi L, Stader F, Braun D, Calmy A, Hachfeld A, Cavassini M, Tarr P, Wissel K, Battegay M, **Marzolini C**. Prescribing issues in the Swiss HIV infected ageing population.
18th annual meeting of the International Society of Pharmacovigilance, Geneva, 11-14 November 2018 (poster).
- 21) Simon A, **Marzolini C**, Vanobberghen F, Burri C, Kuemmerle A. Reporting of QT interval prolongation and Torsade de Pointes for HIV-Antiretrovirals in VigiBase: focus on potential drug-drug interactions.
18th annual meeting of the International Society of Pharmacovigilance, Geneva, 11-14 November 2018 (poster).
- 22) Kummerle A, Sikalengo G, Vanobberghen F, Ndege R, Foe G, Schlaeppi C, Glass TR, Weisser M, **Marzolini C**. Clinical recognition and management of drug-drug interactions in a rural Tanzanian HIV Cohort.
67th ASTMH Annual Meeting, New Orleans, 28th October- 1st November 2018 (poster).
- 23) Schlaeppi C, Glass TR, Sikalengo G, Vanobberghen F, Ndege R, Foe G, Kuemmerle A, Battegay M, **Marzolini C**, Weisser M. Prevalence and management of drug-drug interactions in a rural Tanzanian HIV Cohort.
22nd International AIDS Conference, Amsterdam, 23-27 July 2018 (poster).
- 24) Stader F, Siccardi M, Penny M, Kinvig H, Battegay M, **Marzolini C**. A population database for healthy elderly to inform physiologically-based pharmacokinetic models considering anatomical, physiological and biological system parameters.
27th meeting on Population Approach Group Europe (PAGE), Montreux, 29 May-1 June 2018 (poster).
- 25) Courlet P, Guidi M, Anais G, Cavassini M, Buclin T, **Marzolini C**, Eap C, Decosterd L, Csajka C. Comparison of escitalopram pharmacokinetics in HIV-infected individuals with an uninfected psychiatric cohort.
27th meeting on Population Approach Group Europe (PAGE), Montreux, 29 May-1 June 2018 (poster).
- 26) Livio F, Rustemi F, Moffa G, Elzi L, Stader F, Braun D, Calmy A, Hachfeld A, Cavassini M, Tarr P, Wissel K, Battegay M, **Marzolini C**. Polypharmacy, drug-drug interactions and potentially inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study.
19th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Baltimore, 22-24 Mai 2018 (**short oral presentation**).

- 27) Stader F, Kinvig H, Battegay M, Khoo S, Owen A, Siccardi M, **Marzolini C**. Effective approach to quantify CYP3A4 mediated drug-drug interactions between antiretroviral drugs and co-medications to guide clinical dosing recommendations.
16th European AIDS Conference (EACS), Milano, 25-27 October 2017 (poster).
- 28) **Marzolini C**, Decosterd L, Winterfeld U, Tissot F, Francini K, Buclin T, Livio F. Free and total plasma concentrations of elvitegravir/cobicistat during pregnancy and postpartum. 28th Conference of the European Network of Teratology Information Services, Budapest, 2-5 September 2017 (**short oral presentation**).
- 29) Bartels H, Decosterd L, Battegay M, **Marzolini C**. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir. 18th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Chicago, 14-16 June 2017 (**oral presentation**).
- 30) Roberts O, Carcieri C, **Marzolini C**, Back D, Owen A, Siccardi M. Effects of cobicistat and ritonavir on gene expression in human hepatocytes in vitro. 17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington, 8-10 June 2016 (poster).
- 31) **Marzolini C**, Rajoli R, Battegay M, Back D, Siccardi M. Efavirenz simultaneous induction and inhibition of multiple cytochromes impacts the magnitude of drug-drug interactions.
15th European AIDS Conference (EACS), Barcelona, 21-24 October 2015 (**oral presentation**).
- 32) **Marzolini C**, Rajoli R, Elzi L, Battegay M, Back D, Siccardi M. Pharmacokinetic interactions between antidiabetics and efavirenz using PBPK modeling.
22th Conference on Retroviruses and Opportunistic Infections, Seattle, 23-26 February 2015 (**themed oral discussion**).
- 33) **Marzolini C**, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca B, Fehr J, Bonora S, Torti C, Dauchy FA, Zangele R, Gianotti N, Ghosn J, Mocroft A, Battegay M on behalf of COHERE in EuroCoord. Obese HIV-infected patients treated with efavirenz-containing regimens are at risk of virological failure.
14th European AIDS Conference (EACS), Brussels, 16-19 October 2013 (**oral presentation**).
- 34) **Marzolini C**, Rotger M, Lubomirov R, Cavassini M, Weber R, Furrer H, Bernasconi E, Calmy A, Vernazza P, Telenti A, Battegay M, Elzi L and the Swiss HIV Cohort Study. Effect of SLCO1B1 polymorphism on the lipid lowering response to statins in HIV-infected patients treated with lopinavir/r containing regimens.
14th European AIDS Conference (EACS), Brussels, 16-19 October 2013 (poster).
- 35) Siccardi M, **Marzolini C**, Seden K, Almond L, Kirov A, Khoo S, Owen A, Back D: Prediction of drug-drug interactions between various antidepressants and ritonavir using a physiologically based pharmacokinetic model.
11th International Congress on drug therapy in HIV infection, Glasgow, 11-15 November 2012 (poster).
- 36) Siccardi M, Almond L, Schipani A, Csajka C, **Marzolini C**, Edwards D, Khoo S, Owen A, Back DJ: Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using a physiologically-based dynamic model.
2012 ASCPT Annual Meeting, Maryland, 12-17 March 2012 (poster).
- 37) **Marzolini C**, Mueller R, Battegay M, Seelig A: Permeation of antiretroviral agents across the blood-brain barrier and interactions with efflux drug transporters.
13th European AIDS Conference (EACS), Belgrade, 12-15 October 2011 (**best poster oral presentation**).
- 38) **Marzolini C**, Rotger M, Decosterd L, Telenti A, Csajka C, Bucher H, Rickenbach M, Günthard H, Nicca D, Hirschel B, Bernasconi E, Wandeler G, Battegay M, Glass T and the Swiss HIV Cohort

Study: Determinants of virological suppression in HIV positive patients on antiretroviral therapy with self-reported poor adherence.

13th European AIDS Conference (EACS), Belgrade, 12-15 October 2011 (poster).

- 39) Fasel D, **Marzolini C**, Vuichard D, Elzi L, Battegay M: Etravirine-induced thrombocytopenia. Swiss Society of Infectious Diseases annual meeting, Interlaken, 24-25 August 2011 (poster).
- 40) Glass T, Rotger M, Telenti A, Decosterd L, Bucher H, Rickenback M, Günthard H, Vernazza P, Hirschel B, Bernasconi E, Furrer H, Battegay M, **Marzolini C** and the Swiss HIV Cohort Study: Determinants of virological suppression in HIV positive patients on antiretroviral therapy with self-reported poor adherence. 6th International Conference on HIV treatment and prevention adherence, Miami, 22-24 May 2011 (poster).
- 41) **Marzolini C**, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave JP, Cavassini M, Bernasconi E, Calmy A, Vernazza P, Khoo S, Ledergerber B, Back DJ, Battegay M and the Swiss HIV Cohort members: Prevalence and relevance of drug-drug interactions in the Swiss HIV Cohort Study. 12th European AIDS Conference (EACS), Köln, 11-14 November 2009 (**oral presentation**).
- 42) **Marzolini C**, Elzi L, Gibbons S, Khoo S, Ledergerber B, Back DJ, Battegay M and the Swiss HIV Cohort members: Prevalence of potential drug-drug interactions in the Swiss HIV Cohort Study. 1th Deutsch-Osterreichisch-Schweizerischer AIDS-Kongress (Södak), St Gallen, 24-27 June 2009 (**oral presentation**).
- 43) **Marzolini C**, Gibbons S, Elzi L, Khoo S, Ledergerber B, Battegay M, Back DJ and the Swiss HIV Cohort members. Prevalence of potential drug-drug interactions in the Swiss HIV Cohort Study. 15th Annual Conference of the British HIV Association, Liverpool, 1-3 April 2009 (poster).
- 44) **Marzolini C**, Leake B, Schwarz UI, Chong S, Kim RB: Evaluation of efavirenz transport by P-glycoprotein and uptake transporters. 13th Conference on Retroviruses and Opportunistic Infections, Denver, 5-9 February 2006 (poster).
- 45) Haas DW, Ribaldo H, Kim RB, Tierney C, Wilkinson GR, Gulick R, Clifford D, **Marzolini C**, Acosta EP: Pharmacogenetics of efavirenz and selective pressure for drug resistance after treatment discontinuation: an AACTG study. 12th Conference on Retroviruses and Opportunistic Infections, Boston 22-25 February 2005 (poster).
- 46) **Marzolini C**, Leake BF, Roberts R, Kim RB: Effect of nonsynonymous polymorphisms on multidrug resistance-associated protein 4 (MRP4) expression. 7th International ISSX Meeting, Vancouver 29 August- 2 September 2004 (poster).
- 47) **Marzolini C**, Leake BF, Kim RB: Identification of single nucleotide polymorphisms in the multidrug-associated resistance protein 4 (MRP4). 105th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Miami 24-27 March 2004 (poster).
- 48) **Marzolini C**, Tirona RG, Lee W, Gervasini G, Ho RH, Leake BF, Kim RB: Un-expected complexity in nuclear receptor activation by HIV protease inhibitors and induction of CYP enzymes and transporters. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco 08-11 February 2004 (**oral presentation**).
- 49) Csajka C, **Marzolini C**, Fattinger K, Decosterd LA, Telenti A, Biollaz J, Buclin T: Population pharmacokinetics and effects of indinavir in HIV infected patients.

105th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Washington 02-05 April 2003 (poster).

- 50) Bleiber G, Suarez C, Martinez R, Fellay J, **Marzolini C**, Telenti A: Influence of MDR1 on CD4+ cell permissiveness to HIV-1 infection.
10th Conference on Retroviruses and Opportunistic Infections, Chicago 10-14 February 2003 (poster).
- 51) Fellay J, **Marzolini C**, Greub G, Buclin T, Eap CB, Telenti A: Predictive power of P-glycoprotein and CYP2D6 polymorphisms for plasma levels of antiretroviral agents.
8th Conference on Retroviruses and Opportunistic Infections, Chicago 4-8 February 2001 (oral presentation).
- 52) **Marzolini C**, Greub G, Decosterd LA, Biollaz J, Telenti A, Buclin T: Routine antiretroviral plasma levels of NNRTIs and PIs correlate with viral suppression and adverse events.
8th Conference on Retroviruses and Opportunistic Infections, Chicago 4-8 February 2001 (poster).
- 53) **Marzolini C**, Buclin T, Decosterd LA, Biollaz J, Telenti A: Plasma concentrations of nelfinavir under t.i.d and b.i.d regimens.
13th AIDS Conference, Durban 9-14 July 2000 (poster).
- 54) **Marzolini C**, Telenti A, Buclin T, Biollaz J, Decosterd LA : Therapeutic Drug Monitoring of antiviral drugs in the management of HIV infection.
Symposium scientifique de la Gesellschaft Schweizerischer Amts- und Spitalapotheker (GSASA), Interlaken 10-11 Novembre 1999 (poster), GSASA News 1999, 14 : p 55.
- 55) **Marzolini C**, Telenti A, Buclin T, Biollaz J, Decosterd LA : Suivi thérapeutique des médicaments antiviraux dans le traitement de l'infection VIH.
9^{eme} Journée Franco-Suisse de Pharmacie Hospitalière, Mâcon 21-22 Octobre 1999 (poster).
- 56) **Marzolini C**, Vodoz A-L : Soins palliatifs : une expérience nouvelle avec une équipe pluridisciplinaire à domicile.
5th Congress of the European Association for Palliative Care, London 10-13 September 1997 (poster).
- 57) Gander M, Leyvraz S, Bauer J, Shen F, **Marzolini C**, Bonfanti M, Collella G, Decosterd LA, Biollaz J, D'Incalci M and Lejeune F : Association of temozolomide (TMZ) and fotemustine (Fote) : an approach based on O⁶ alkylguanine-DNA alkyl transferase (AT) depletion.
9th NCI-EORTC Symposium on new drugs in cancer therapy, Amsterdam 15-18 March 1996 (poster), Ann Oncol, 1996, 7 : p 439.

Invited speaker for international and national talks

- 1) **Marzolini C**. Deprescribing: the fight back against polypharmacy.
15th Residential course on clinical pharmacology of antiretrovirals, Torino, 15-17 January 2020 (mini-lecture).
- 2) **Marzolini C**. Polypharmacy, drug-drug interactions and inappropriate and prescribing errors in elderly PLWH.
Post-graduate medical training, Regional Hospital Bellinzona, 27 November 2019.
- 3) **Marzolini C**. DDI panel.
17th European AIDS Conference (EACS), Basel, 6-9 November 2019.
- 4) **Marzolini C**: Polypharmacy, drug-drug interactions and inappropriate prescribing errors in elderly PLWH.
21st International Workshop on Comorbidities and Adverse Drug Reactions in HIV, Basel, 4-6 November, 2019.

- 5) **Marzolini C.** Polypharmacy making complex matters simple.
HIV Stand Alone scientific symposium, Lisbon, October 12, 2019.
- 6) **Marzolini C:** Drug-drug interactions.
Post graduate medical training (Dienstagsclub), University hospital Bern, 10 September 2019.
- 7) **Marzolini C.** Antiviral therapy in elderly individuals living with HIV.
10th IAS Conference on HIV Science, Mexico City, 21-24 July, 2019.
- 8) **Marzolini C.** Considerations for polypharmacy in clinical practice.
10th IAS Conference on HIV Science, Mexico City, 21-24 July, 2019.
- 9) **Marzolini C:** Top DDIs in clinical practice. Still relevant?
2nd Update on clinical topics in antiretroviral therapy, Barcelona, 30-31 May, 2019.
- 10) **Marzolini C:** Treatment of children living with HIV.
17th Congress of the European Society of Developmental Perinatal and Paediatric Pharmacology, Basel, 28-30 May, 2019.
- 11) **Marzolini C:** Clinical case presentation on polypharmacy.
20th International Workshop on Clinical Pharmacology of HIV, hepatitis & other antiviral drugs, Noordwijk, 14-16 Mai, 2019.
- 12) **Marzolini C:** Drug-drug interactions in HIV therapy.
17th Innsbruck HIV Update, Kühtai, 4-5 Mai, 2019.
- 13) **Marzolini C:** Polypharmacy and DDI: making a complex matter simple.
MSD symposium, Buenos Aires, 28-30 March 2019.
- 14) **Marzolini C:** Polypharmacy in HIV and HCV patients: not only drug interactions.
14th Residential course on clinical pharmacology of antiretrovirals, Torino, 16-18 January 2019 (mini-lecture).
- 15) **Marzolini C:** Criteri di appropriatezza prescrittiva nell'anziano.
Polypharmacy: l'importanza della gestione multidisciplinare – focal point workshop 2018, Milano, 13 December 2018.
- 16) **Marzolini C:** News from the HIV Glasgow Conference.
Post graduate medical training (Dienstagclub), University hospital Basel, 13 November 2018.
- 17) **Marzolini C:** The top 10 DDIs in day to day clinical management of HIV. 14th International Congress on drug therapy in HIV infection, Glasgow, 28-31 October 2018 (plenary talk).
- 18) **Marzolini C:** Polypharmacy and DDI: making a complex matter simple.
MSD symposium, Rome, 28-29 September 2018.
- 19) **Marzolini C:** Gestion des interactions: anticoagulants et psychotropes.
8^{ème} Congrès VIH sur les Complications et Comorbidités, Biarritz, 20-21 Septembre 2018.
- 20) **Marzolini C:** Polypharmacy
9th International Workshop on HIV & Aging, New York, 13-14 September 2018 (plenary talk).
- 21) **Marzolini C:** Polypharmacy and DDI in an aging population.
22nd International AIDS Conference, Amsterdam, 23-27 July 2018.
- 22) **Marzolini C:** Drug-drug interactions with HIV therapy.
Post graduate medical training, Division of Infectious Diseases, University S. Raffaele, Milano, 15 June 2018.
- 23) **Marzolini C:** The SHCS and me: a love story with a future?
30 years celebration of the Swiss HIV Cohort Study, Zürich, 7 June 2018.

- 24) **Marzolini C:** Prescribing issues in elderly individuals living with HIV.
Post graduate medical training, Division of Clinical Pharmacology, Johns Hopkins Medical School, Baltimore, 25 May 2018.
- 25) **Marzolini C:** Psychotropic medications, recreational drugs and antiretrovirals.
11th International Symposium on HIV and Neuropsychiatry, Barcelona, 18-19 May 2018.
- 26) **Marzolini C:** General prescribing in the elderly: iatrogenic triad and cART.
1st Geriatric HIV Medicine Summit, Rome, 5-6 February 2018 (mini-lecture).
- 27) **Marzolini C:** I criteri STOPP/START per gestire la polypharmacy nella popolazione HIV anziana.
La gestione della polypharmacy nel paziente anziano, Torino, 17 January 2018 (mini-lecture).
- 28) **Marzolini C:** Management of polypharmacy in the aging patient.
13th Residential course on clinical pharmacology of antiretrovirals, Torino, 17-19 January 2018 (mini-lecture).
- 29) **Marzolini C:** Interactions médicamenteuses au sens large du terme.
State of the HAART: HIV and the Body, Geneva, 7 December 2017 (oral presentation).
- 30) **Marzolini C:** Psychotropic medications, recreational drugs and antiretrovirals.
16th European AIDS Conference, Milano, 25-27 October 2017 (oral presentation).
- 31) **Marzolini C:** Drug-drug interactions section in the EACS Guidelines.
16th European AIDS Conference, Milano, 25-27 October 2017 (oral presentation).
- 32) **Marzolini C:** How to handle polypharmacy best.
16th European AIDS Conference, Milano, 25-27 October 2017 (oral presentation).
- 33) **Marzolini C:** Drug-drug interactions in the HIV positive aging patient.
Post graduate medical training, University hospital of Zürich, 15 Mai 2017
- 34) **Marzolini C:** Therapeutic challenges in the aging HIV infected individuals.
Post graduate medical training, University hospital of Basel, 16 Basel 2017
- 35) **Marzolini C:** State-of-the-art short presentation on Intracellular and tissue pharmacology.
24th Conference on Retroviruses and Opportunistic Infections, Seattle, 13-16 February 2017.
- 36) **Marzolini C:** Drug-drug interactions in the HIV-infected aging patient.
12th Residential course on clinical pharmacology of antiretrovirals, Torino, 18-20 January 2017 (mini-lecture).
- 37) **Marzolini C:** Drug-drug interactions with antiretrovirals.
Post graduate training for physicians of the emergency department of the University Hospital of Basel, 21 October 2016
- 38) **Marzolini C & Decosterd L:** Drug-drug interactions in the aging HIV infected patients: modeling and simulations approaches.
Scientific retreat of the Swiss HIV Cohort Study, Bern, 22 June 2016.
- 39) **Marzolini C:** Will we see the Back of DDIs ?
17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, Washington, 8-10 June 2016 (mini-lecture).
- 40) **Marzolini C:** Drug-drug interactions in the HIV aging patient.
Post graduate medical training (Dienstagclub), University hospital of Bern, 31 May 2016.
- 41) **Marzolini C.** CNS pharmacology of antiretroviral drugs and drug interactions between antiretroviral and CNS drugs.
Post graduate medical training (Dienstagclub), University hospital Basel, 5 April 2016.

- 42) **Marzolini C:** Diffusion des médicaments antirétroviraux dans les réservoirs : mise au point et défis.
8^{ème} Conférence Francophone VIH/Hépatites, Brussels, 20-23 April 2016 (mini-lecture).
- 43) **Marzolini C:** Pharmacology of antiretroviral drugs in the aging patient and drug-drug interactions.
1st conference on new challenges and unmet needs of people living with HIV/AIDS aged 50+, Berlin, 31 March – 3 April 2016 (mini-lecture).
- 44) **Marzolini C:** Drug-drug interactions in the aging patient.
11th Residential course on clinical pharmacology of antiretrovirals, Torino, 20-22 January 2016 (mini-lecture).
- 45) **Marzolini C, Back D.** Meet-the-expert: HIV HCV drug drug interactions.
15th European AIDS Conference (EACS), Barcelona, 21-24 October 2015 (workshop).
- 46) **Marzolini C:** Drug-drug interactions with direct acting antivirals against HCV.
Post graduate medical training (Dienstagsclub), University hospital Bern, 15 September 2015.
- 47) **Marzolini C:** Pharmacologie du CNS et interactions médicamenteuses entre antirétroviraux et médicaments du CNS.
Post-graduate medical training, University hospital of Lausanne, 16 July 2015
- 48) **Marzolini C:** CNS pharmacology of antiretroviral drugs and relevant interactions between antiretroviral and CNS drugs.
8th International Symposium on HIV and Neuropsychiatry, Barcelona, 12-13 June 2015.
- 49) **Marzolini C, Elzi L:** Drug-drug interactions in the aging patient.
1st Swiss HIV Cohort Study metabolic and aging workshop, Basel, 4-5 June 2015.
- 50) **Marzolini C:** New issues in management of drug-drug interactions.
10th Residential course on clinical pharmacology of antiretrovirals, Torino, 21-23 January 2015 (mini-lecture).
- 51) **Marzolini C:** Novel approaches and insights of HIV drug-drug interactions.
Swiss Society for Infectious Diseases, Hospital Epidemiology and Tropical Medicine, Aarau, 28-29 August 2014.
- 52) **Marzolini C:** Pharmacology of integrase inhibitors.
SHCS full Assembly, Bern, 5 June 2014 (state-of-the-art lecture).
- 53) **Marzolini C:** Interactions médicamenteuses avec les thérapies antirétrovirales: mécanismes et relevance clinique.
7^{ème} Conférence Francophone VIH, Montpellier, 27-30 April 2014 (mini-lecture).
- 54) **Marzolini C:** New issues in management of drug-drug interactions.
9th Residential course on clinical pharmacology of antiretrovirals, Torino, 15-17 January 2014 (mini-lecture).
- 55) **Marzolini C:** Drug-drug interactions.
14th European AIDS Conference (EACS), Brussels, 16-19 October 2013 (mini-lecture).
- 56) **Marzolini C:** Drug-drug interactions with antiretroviral agents: mechanisms and clinical relevance.
Post graduate medical training, University hospital Bern, 9 September 2013.
- 57) **Marzolini C:** Drug-drug interactions between antiretroviral agents and hepatitis C, cancer chemotherapy, non-oral medications.

11th Int. Congress on drug therapy in HIV infection, Glasgow, 11-15 November 2012 (panel discussion).

- 58) **Marzolini C**, Ciaffi L: Gestion d'une interaction médicamenteuse. 6ème Conférence Francophone VIH, Geneva, 25-28 march 2012.
- 59) **Marzolini C**: Drug-drug interactions between antiretroviral agents and antidepressants. Post graduate medical training, University hospital Zürich, 7 February 2012.
- 60) **Marzolini C**: Drug-drug interactions between antiretroviral agents and cardiovascular drugs. 10th Int. Congress on drug therapy in HIV infection, Glasgow, 7-11 November 2010.
- 61) **Marzolini C**: Prévalence des interactions médicamenteuses chez les patients de la SHCS. Post graduate medical training, University hospital Geneva, 3 September 2009.
- 62) **Marzolini C**: Placental transfer of antiretroviral drugs. Pediatric ACTG Winter Group Meeting, Baltimore 1-4 December 2004 (state-of-the art lecture).

Invited congress session chair

- 1) **Marzolini C** & Khoo S: Cases presentation and oral poster discussion session: Pharmacology today and tomorrow. 17th European AIDS Conference (EACS), Basel, 6-9 November 2019.
- 2) **Marzolini C**: Lead of themed poster discussion on Intracellular and tissue pharmacology. 24th Conference on Retroviruses and Opportunistic Infections, Seattle, 13-16 February 2017.
- 3) **Marzolini C** & Khoo S: Oral poster discussion session: Pharmacology, pharmacogenomics and drug-drug interactions. 15th European AIDS Conference (EACS), Barcelona, 21-24 October 2015.
- 4) **Marzolini C** & Back D: Poster discussion session: Clinical Pharmacology. 11th Int. Congress on drug therapy in HIV infection, Glasgow, 11-15 November 2012.

Media interview/educational videos

- 1) **Marzolini C**. HIV management – DDIs in 2020. Are they still relevant matter? Educational video for the Spanish Society of Infectious Diseases and Microbiology (SEIMC) and the AIDS Spanish Group (GESIDA), November 2019.
- 2) **Marzolini C**. Quelle place pour la pharmacocinétique cellulaire des antirétroviraux? Post CROI interview for « La lettre de l'Infectiologue », February 15 2017.
- 3) **Marzolini C** : The basics of drug-drug interactions. Educational video posted in the website: www.HIV-druginteractions.org, December 8, 2016.
- 4) **Marzolini C** : Herbal and complementary medicine interactions. Educational video posted in the website: www.HIV-druginteractions.org, December 8, 2016.
- 5) **Marzolini C** : Drug interactions in an aging HIV population. Educational video posted in the website: www.HIV-druginteractions.org, December 8, 2016.

Abstracts reviewer for international conferences

- 1) 23th International AIDS Conference, San Francisco, 6-10 July 2020
- 2) 15th International Congress on drug therapy in HIV infection, Glasgow, 4-7 October 2020
- 3) 17th European AIDS Conference (EACS), Basel, 6-9 November 2019
- 4) 21st International workshop on comorbidities and adverse drugs reactions in HIV, Basel, 5-6 November 2019

- 5) 14th International Congress on drug therapy in HIV infection, Glasgow, 28-31 October 2018
- 6) 22nd International AIDS Conference, Amsterdam, 23-27 July 2018
- 7) 15th European AIDS Conference, Barcelona, October 21-24, 2015
- 8) 13th European AIDS Conference, Brussels, October 16-19, 2013

Ad hoc reviewer for the following journals

Antiviral Therapy, Clinical Infectious Diseases, Journal of Antimicrobial Chemotherapy, HIV Medicine, Journal of Clinical Pharmacology, Clinical Pharmacokinetics, International Journal of STD & AIDS.

Students supervision/visiting Professors

Master student: Flamur Rrustemi, medical student at the University of Basel (2016-2018)

PhD student: Felix Stader, Faculty of Sciences, University of Basel (February 2017- March 2020). PhD graduation with Summa cum Laude (grade 6.0/6.0).

PhD student: Hannah Kinvig, University of Liverpool + University of Basel (2017-) (PhD student co-shared between the two Universities)

Visiting Professor: Bernadette Jakeman, Associate Professor, College of Pharmacy, University of New Mexico, Albuquerque, USA (May-July 2019)

External expert of PhD thesis/Professor nomination

- | | |
|------|---|
| 2020 | External expert of the PhD thesis “Pharmacokinetics, pharmacodynamics and pharmacogenetics of the new integrase inhibitor, dolutegravir, and new pharmacological booster, cobicistat, in the treatment of HIV”. PhD candidate: Emilie Elliot, University of Liverpool. |
| 2019 | External expert for the nomination of Dr P. Nowak to the rank of Assistant Professor. University of Geneva. |
| 2018 | External expert of the PhD thesis “Assessment of the inter-individual variation observed between patients receiving HIV antiretroviral therapy”. PhD candidate: Megan Neary, University of Liverpool. |
| 2014 | External expert of the PhD thesis “Understanding the function of the membrane transporter ABCG2 by comparison with P-glycoprotein: interaction with antitumorals, antibiotics, hormones and other compounds” PhD candidate: Estefania Egido de Frutos, University of Leon, Spain. |
| 2014 | External expert of the PhD thesis “Therapeutic drug monitoring and metabolite profile analysis of antiviral drugs”. PhD candidate: Manel Aouri, University of Lausanne. |

Allogol

Basel, June 9th, 2020